Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

PHASE 1B OPEN-LABEL STUDY OF THE SAFETY AND CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066) IN TUMORS WITH GENETIC EVENTS INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK ) GENE LOCUS

This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.

Inclusion Criteria:

• histologically or cytologically proven diagnosis of malignancy other than NSCLC
• positive for translocation or inversion event involving the ALK gene locus
• positive for ALK amplification events
• positive for ALK activating point mutations

Exclusion Criteria:

• mutations of amplifications involving the c-Met gene but not the ALK gene
• concurrent treatment on another therapeutic clinical trial
• prior therapy specifically directed against ALK